No title
The use of monoclonal antibodies in cancer treatment is on the rise demanding therapeutic antibodies to novel targets. To properly analyze these therapeutic candidates, state-of-the-art control antibodies are important to minimize false-negative and false-positive signals. The current negative control antibody at BioInvent International displays increased background signals, resulting in more stri
